Compositions and methods of treating retinal disease
AssigneeAldeyra Therapeutics, Inc.
InventorsThomas A. Jordan, John E. Dowling, John Clifford Chabala
Life of this patent
Estimating the term…
Abstract
Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed
Claims21
1-33. (canceled)
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof;
- and a pharmaceutically acceptable carrier.
A method of treating macular degeneration in a subject, the method comprising administering to the subject a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
A method of treating a retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin in a subject, comprising administering to the subject a compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.